Private company
TILT Holdings Inc.
In its 2025 annual report the company says: “TILT is a business solutions provider to the global cannabis industry offering a diverse range of value-added products and services to industry participants. The Company operates through two business divisions: Inhalation Technology and Cannabis. Through the Inhalation Technology division, the Company sells vape and accessory products and services to brand partners and cannabis retailers in regulated markets across 40 states in the U.S., and internationally in Canada, South America, and the European Union.”4 It is headquartered in Vancouver, Canada.1
Last updated Oct 20, 2026.
Overview
- IndustryCigarettes1
- HeadquartersVancouver, Canada1
- Incorporated inBritish Columbia, Canada2
- Business addressSuite 2200, 885 West Georgia Street, Vancouver, A1 V6C 3E82
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
TILT is a business solutions provider to the global cannabis industry offering a diverse range of value-added products and services to industry participants. Through a portfolio of companies providing technology, hardware, cultivation, production, TILT services brands and cannabis retailers in regulated markets across 40 states in the U.S., as well as Canada, South America, and the European Union.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue83¢$95.6M
- Other costs13¢$15.3M
- Income tax4¢$4.7M
Out of $115.6M in revenue.5 The company lost money this year.
Financial statements
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $202.7M6 | $174.2M7 | $166.0M5 | $115.6M5 | |
| Cost of revenue | $152.5M6 | $136.0M7 | $141.6M5 | $95.6M5 | |
| Gross profit | $50.2M6 | $38.2M7 | $24.4M5 | $20.1M5 | |
| Operating expenses | $90.0M6 | $129.0M7 | $67.5M5 | $89.5M5 | |
| Operating income | -$39.8M6 | -$90.9M7 | -$43.2M5 | -$69.4M5 | |
| Interest | $10.4M6 | $14.2M7 | $21.0M7 | ||
| Income before tax | -$49.0M6 | -$104.5M7 | -$67.2M5 | -$94.9M5 | |
| Income tax | -$13.9M6 | $3.0M7 | -$3.3M5 | $4.7M5 | |
| Net income | -$35.1M6 | -$107.5M7 | -$62.4M5 | -$99.7M5 | |
| Earnings per share | -$0.096 | -$0.297 | -$0.165 | -$0.265 | |
| Earnings per share (diluted) | -$0.096 | -$0.297 | -$0.165 | -$0.265 | |
| Shares (weighted, basic) | 370.0M shares6 | 375.5M shares7 | 379.6M shares5 | 388.7M shares5 | |
| Shares (weighted, diluted) | 370.0M shares6 | 375.5M shares7 | 379.6M shares5 | 388.7M shares5 |
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Cash | $8.9M6 | $7.0M7 | $3.5M5 | $3.3M5 | $4.3M5 |
| Inventory | $55.6M6 | $52.9M7 | $32.9M5 | $22.5M5 | |
| Current assets | $100.6M6 | $85.9M7 | $56.3M5 | $40.8M5 | |
| Property, plant and equipment | $62.4M6 | $67.9M7 | $51.2M5 | $30.7M5 | |
| Goodwill | $70.5M7 | $20.8M5 | $17.7M5 | $17.7M5 | |
| Intangible assets | $128.8M6 | $102.7M5 | $84.8M5 | $44.5M5 | |
| Total assets | $381.3M6 | $294.0M7 | $231.2M5 | $151.3M5 | |
| Accounts payable | $37.8M6 | $49.3M7 | $46.3M5 | $50.3M5 | |
| Current liabilities | $99.5M6 | $125.5M7 | $76.1M5 | $87.5M5 | |
| Long-term debt | $86.6M6 | $59.7M6 | |||
| Total liabilities | $155.7M6 | $172.5M7 | $168.8M5 | $188.5M5 | |
| Retained earnings | -$856.2M6 | -$963.7M7 | -$1.0B5 | -$1.1B5 | |
| Shareholders’ equity | $264.7M6 | $225.5M6 | $121.4M7 | $62.4M5 | -$37.2M5 |
| Shares outstanding | 374.1M shares6 | 377.5M shares7 | 384.8M shares5 | 391.2M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Cash from operations | -$8.6M6 | $8.6M7 | $5.4M5 | -$189.0K5 | |
| Depreciation and amortization | $22.4M6 | $23.9M7 | $21.6M5 | $19.3M5 | |
| Stock-based compensation | $3.8M6 | $3.3M7 | -$1.7M5 | $83.0K5 | |
| Capital spending | $3.1M6 | $15.1M7 | $713.0K5 | $892.0K5 | |
| Free cash flow | -$11.7M | -$6.5M | $4.7M | -$1.1M | |
| Cash from investing | $186.0K6 | -$16.8M7 | $13.2M5 | -$742.0K5 | |
| Cash from financing | $6.5M6 | $4.8M7 | -$18.7M5 | $1.9M5 |
Corporate structure
TILT Holdings Inc. sits at the top of its group. 18 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of TILT Holdings Inc.
- Deyong Wang Filed SC 13G on TILT Holdings Inc., latest Mar 23, 2023
- Mark Scatterday Filed SC 13G/A on TILT Holdings Inc., latest Feb 27, 2023 (2 filings since Feb 13, 2023)
- Robert Crompton Filed SC 13G on TILT Holdings Inc., latest Feb 27, 2023
- TILT Holdings Inc. Vancouver, Canada
- 1. Commonwealth Alternative Care, Inc. Subsidiary · Massachusetts, United States
- 11. White Haven RE, LLC Subsidiary · Pennsylvania, United States
- 12. Jimmy Jang Holdings Inc. Subsidiary · British Columbia, Canada
- 13. SH Therapeutics, LLC Subsidiary · Florida, United States
- 14. SF Ohio, Inc. Subsidiary · Ohio, United States
- 15.. SH Realty Holdings, LLC Subsidiary · Delaware, United States
- 16. SH Realty Holdings-Ohio, LLC Subsidiary · Ohio, United States
- 17. Sante Veritas Holdings Inc. Subsidiary · British Columbia, Canada
- 18. Sante Veritas Therapeutics Inc. Subsidiary · British Columbia, Canada
- 2. Standard Farms LLC Subsidiary · Pennsylvania, United States
- 3. Standard Farms Ohio, LLC Subsidiary · Ohio, United States
- 4. Jupiter Research, LLC Subsidiary · Arizona, United States
- 5. Baker Technologies Inc. Subsidiary · Delaware, United States
- 6. Sea Hunter Therapeutics, LLC Subsidiary · Delaware, United States
- 7. JJ Blocker Co. Subsidiary · Delaware, United States
- 8. Jimmy Jang L.P. Subsidiary · Delaware, United States
- 9. SFNY Holdings, Inc. Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What TILT Holdings Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $82.4M5 Dec 31, 2024 | $83.1M5 Dec 31, 2023 | −0.8% |
| Accumulated depreciation | $51.7M5 Dec 31, 2024 | $31.9M5 Dec 31, 2023 | +61.9% |
| Property and equipment, net | $30.7M5 Dec 31, 2024 | $51.2M5 Dec 31, 2023 | −40.0% |
| Finance-lease assets | $1.5M5 Dec 31, 2024 | $2.2M5 Dec 31, 2023 | −34.9% |
| Operating-lease assets (leased space) | $11.9M5 Dec 31, 2024 | $12.3M5 Dec 31, 2023 | −2.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Stakes in other companies (equity method) | $1.0K5 Dec 31, 2023 | $6.4M7 Dec 31, 2022 | −100.0% |
| Long-term investments | $1.0K5 Dec 31, 2023 | $6.4M7 Dec 31, 2022 | −100.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $17.7M5 Dec 31, 2024 | $17.7M5 Dec 31, 2023 | 0% |
| Intangible assets, net (excluding goodwill) | $44.5M5 Dec 31, 2024 | $84.8M5 Dec 31, 2023 | −47.5% |
| Accumulated amortization | $115.4M5 Dec 31, 2024 | $75.2M5 Dec 31, 2023 | +53.6% |
| Finite-lived intangibles, net | $42.3M5 Dec 31, 2024 | $82.6M7 Dec 31, 2023 | −48.7% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $22.5M5 Dec 31, 2024 | $32.9M5 Dec 31, 2023 | −31.6% |
| Raw materials | $2.2M5 Dec 31, 2024 | $2.7M5 Dec 31, 2023 | −17.4% |
| Work in process | $9.9M5 Dec 31, 2024 | $13.4M5 Dec 31, 2023 | −26.1% |
| Finished goods | $9.1M5 Dec 31, 2024 | $14.8M5 Dec 31, 2023 | −38.6% |
| Supplies | $891.0K5 Dec 31, 2024 | $1.6M5 Dec 31, 2023 | −45.5% |
Properties, in its own words
Leases
The following table sets forth the Company’s principal properties as of December 31, 2024:
The rest of Item 2
Location · Square Feet · Purpose · Segment · Leased/Owned
Phoenix, AZ · 13,115 · Administrative/R&D · Accessories/Corporate · Leased
Cambridge, MA · 9,882 · Retail (medical only dispensary) · Cannabis · Leased
Taunton, MA · 539,273 · * · Cultivation, manufacturing/processing, and retail sale/distribution · Cannabis · Leased
Taunton, MA · 20,000 · Retail sale/distribution · Cannabis · Leased
Brockton, MA · 6,000 · Retail sale/distribution · Cannabis · Leased
Garfield Heights, OH · 24,314 · Manufacturing/processing and distribution · Cannabis · Leased
Elyria, OH · 6,180 · Vacant · Cannabis · Owned
White Haven Borough, PA · 478,724 · * · Cultivation, manufacturing/processing, and distribution · Cannabis · Leased
Total Square Footage · 1,097,488
* Represents total square footage of parcel
All properties are subject to liens by creditors as described in Note 11 — Notes Payable to the consolidated financial statements for the fiscal year ended December 31, 2024.
Item 2 of the 10-K filed Apr 10, 2025.4
Leadership
Who has led TILT Holdings Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerTimothy Alan Conder Jun 15, 2023 to Jul 2, 202410
- Chief executive officerGary F. Santo Jr. Jun 21, 2022 to Jan 4, 202311
- Chief financial officerDana Russell Arvidson Jan 4, 2023 to Jan 4, 202312
- Chief financial officerBrad Hoch Jun 21, 2022 to Aug 17, 202313
- Chief operating officerDana Russell Arvidson Jun 21, 2022 to Jun 21, 202214
Board members and other officers (10)
- Chief Revenue OfficerNathaniel Christopher Kelly Dec 12, 2022 to Mar 5, 202415
- Board memberMarshall Horowitz Oct 4, 2024 to Oct 4, 202416
- Board memberAdam R. Draizin Feb 17, 2023 to Oct 1, 202417
- Board memberGeorge Odden Mar 16, 2023 to Oct 1, 202418
- Board memberArthur Smuck Jun 14, 2023 to Oct 1, 202419
- Board memberD'Angela Simms Jun 21, 2022 to Jun 7, 202320
- Board memberJane Batzofin Jun 21, 2022 to Jan 4, 202321
- Board memberJohn R. Barravecchia Jun 21, 2022 to Oct 1, 202422
- Board memberMark Scatterday Jun 21, 2022 to Jun 21, 202223
- Board memberTimothy Alan Conder Jun 21, 2022 to Jul 2, 202424
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 1. Commonwealth Alternative Care, Inc. Massachusetts3
- 11. White Haven RE, LLC Pennsylvania3
- 12. Jimmy Jang Holdings Inc. British Columbia3
- 13. SH Therapeutics, LLC Florida3
- 14. SF Ohio, Inc. Ohio3
- 15.. SH Realty Holdings, LLC Delaware3
- 16. SH Realty Holdings-Ohio, LLC Ohio3
- 17. Sante Veritas Holdings Inc. British Columbia3
- 18. Sante Veritas Therapeutics Inc. British Columbia3
- 2. Standard Farms LLC Pennsylvania3
- 3. Standard Farms Ohio, LLC Ohio3
- 4. Jupiter Research, LLC Arizona3
- 5. Baker Technologies Inc. Delaware3
- 6. Sea Hunter Therapeutics, LLC Delaware3
- 7. JJ Blocker Co. Delaware3
- 8. Jimmy Jang L.P. Delaware3
- 9. SFNY Holdings, Inc. Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Nov 20, 20258-K Other events27
- Nov 14, 20258-K Other events28
- Nov 10, 20258-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation29
- Nov 7, 20258-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation30
- Aug 22, 20258-K Entered a material agreement; Completed an acquisition or sale31
- Aug 14, 20258-K Results of operations32
- Aug 5, 20258-K Entered a material agreement; Other events33
- Jun 18, 20258-K Shareholder vote; Other events34
- May 15, 20258-K Results of operations35
- Apr 3, 20258-K Debt or obligation accelerated36
- Mar 19, 20258-K Results of operations37
- Feb 3, 20258-K Entered a material agreement; Other events38
- Jun 15, 2023New chief executive Timothy Alan Conder becomes CEO10
- Jun 21, 2022New chief executive Gary F. Santo Jr. becomes CEO11
Calendar
When it reported results
- Aug 14, 2025Reported quarterly or annual results32
- May 15, 2025Reported quarterly or annual results35
- Mar 19, 2025Reported quarterly or annual results37
- Nov 14, 2024Reported quarterly or annual results39
- Aug 9, 2024Reported quarterly or annual results40
- May 15, 2024Reported quarterly or annual results41
- Mar 14, 2024Reported quarterly or annual results42
- Nov 13, 2023Reported quarterly or annual results43
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
151 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 48 major events, 61 insider forms, 4 large holders, 6 private raises, 19 other. The latest 20:
- Dec 31, 202515-12G EDGAR
- Dec 31, 2025S-8 POS EDGAR
- Nov 20, 20258-K EDGAR
- Nov 14, 20258-K EDGAR
- Nov 10, 20258-K/A EDGAR
- Nov 7, 20258-K EDGAR
- Aug 22, 20258-K EDGAR
- Aug 14, 202510-Q EDGAR
- Aug 14, 20258-K EDGAR
- Aug 5, 20258-K EDGAR
- Jun 18, 20258-K EDGAR
- May 15, 202510-Q EDGAR
- May 15, 20258-K EDGAR
- Apr 25, 2025DEF 14A EDGAR
- Apr 10, 202510-K EDGAR
- Apr 3, 20258-K EDGAR
- Mar 31, 2025NT 10-K EDGAR
- Mar 19, 20258-K EDGAR
- Feb 3, 20258-K EDGAR
- Nov 14, 202410-Q EDGAR
The 151 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2023 | Hoch BradInterim CFO | Buy | 100,000 | $0.28 | $28.0K | Form 4 |
| Jun 13, 2023 | Conder Timothy AlanChief Executive Officer | Buy | 75,000 | $0.04 | $3.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Deyong WangSC 13G, 1 filing Mar 23, 202344
- Mark ScatterdaySC 13G/A, 2 filings Feb 13, 2023 to Feb 27, 202345
- Robert CromptonSC 13G, 1 filing Feb 27, 202346
Money raised
Private offerings the company reported to the SEC on Form D.
- May 15, 2023Raised $4.5 million in a private offering of debt Form D: 6 investors so far Form D
- Feb 15, 2023Raised $52.8 million in a private offering of debt Form D: 6 investors so far Form D
- Nov 22, 2019Filed a private offering of securities Form D: $299,159 offered in all Form D
- Nov 22, 2019Filed a private offering of securities Form D: $5.6 million offered in all Form D
SEC filer profile
How TILT Holdings Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTILT Holdings Inc.1
- CIK0001761510
- Employer ID (EIN)83-20972934
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inBritish Columbia4
- Fiscal year endsDecember 311
- Industry code (SIC)2111 Cigarettes1
- SEC reviewing officeOffice of Manufacturing, Division of Corporation Finance1
- Business addressSuite 2200, 885 West Georgia Street, Vancouver, A1 V6C 3E81
- Phone(647) 777-17131
- Shares outstanding347,463,688 as of Jul 31, 20259
- Public float$7.3M as of Jun 30, 20244
- AuditorHaynie & Company, Salt Lake City, Utah PCAOB ID 457; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceDec 27, 20181
- Filings157 in all: 4 (45), 8-K (44), 3 (16), 10-Q (10), D (6), D/A (6), 8-K/A (4), 10-K (3)1
All 21 form types
DEF 14A (3), SC 13G (3), UPLOAD (3), 10-12G/A (2), ARS (2), CORRESP (2), DEFA14A (2), 10-12G (1), 15-12G (1), NT 10-K (1), S-8 (1), S-8 POS (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Apr 10, 2025
Quarterly report (10-Q) Aug 14, 2025
Proxy statement (DEF 14A) Apr 25, 2025
Latest 8-K (8-K) Nov 20, 2025
Risk factors and legal proceedings
The risks TILT Holdings Inc. names in Item 1A of its 10-K filed Apr 10, 2025: 76 risks under these headings, as written.4
- Risks Related to Regulation and the Cannabis Industry
- Some of our current and planned business activities, while compliant with applicable U.S. state and local law, are illegal under U.S. federal law.
- We are dependent on regulatory approvals and licenses to conduct our business, and there is no assurance that our licenses will be issued, extended or renewed by each applicable regulatory authority.
- The success of our business strategy depends on the legality of the cannabis industry, which industry is subject to change at both the state and federal level.
- FDA regulation of medical cannabis may cause novel regulatory compliance and registration requirements.
- Our growth and development may be hindered by applicable limitations on ownership of licenses.
- We are subject to those risks inherent in an agricultural business.
- We may be adversely impacted by rising or volatile energy costs.
- Due to the classification of cannabis as a Schedule I controlled substance under the CSA, third parties may fail to establish or maintain business relationships with us, which could have a material adverse effect on us.
- Due to the classification of cannabis as a Schedule I controlled substance under the CSA, banks and other financial institutions which service the cannabis industry are at risk of violating certain financial laws, including anti-money laundering statutes, and if we do not have access to traditional banking and financial services in the jurisdictions in which we operate, our business and operations could be materially adversely affected.
- If our operations were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under federal statutes noted or any other applicable legislation, which could restrict or otherwise jeopardize our ability to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada, and subject us to civil and/or criminal penalties.
- Reclassification of cannabis in the U.S. could adversely impact our business and growth strategy.
The other 65 risks
- We may be subject to federal and state forfeiture laws which, if exercised, could have a material adverse impact on our operations.
- The results of future clinical research may be unfavorable to cannabis which may have a material adverse effect on the demand for our products.
- Our operations in the U.S. and any future operations or investments may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada.
- Regulatory changes may adversely affect our profitability or cause us to cease operations entirely.
- State regulatory agencies may require us to post bonds or significant fees, which may be economically prohibitive.
- We may incur significant tax liabilities due to limitations on tax deductions and credits under the applicable sections of the Internal Revenue Code.
- We may not be able to accurately forecast our operating results and plan our operations due to uncertainties in the cannabis industry.
- If we were to experience a bankruptcy, there is no guarantee that U.S. federal bankruptcy protections would be available to our U.S. operations, which would materially adversely affect our prospects and the rights of our lenders and securityholders.
- Public opinion and perception may significantly influence government policy and regulation of the cannabis industry, which could have a material adverse effect on our business, results of operations and prospects.
- We face risks due to industry immaturity or limited comparable, competitive or established industry best practices.
- We may face opposition from other industries, which could have an adverse impact on our business.
- We face intense competition from other companies and increasing legalization of cannabis and rapid growth and consolidation in the cannabis industry may further intensify competition.
- We may face risks associated with competitive illicit enterprises dealing in cannabis.
- There remains doubt and uncertainty that we will be able to legally enforce contracts we enter into.
- The Rohrabacher-Farr Amendment may not be renewed, potentially resulting in DOJ enforcement activities against entities in the cannabis industry.
- We could be materially adversely impacted due to restrictions under U.S. border entry laws.
- Uncertainty in regulatory changes in relation to vaporization devices could result in an impact to our interstate commerce, registration and revenue reporting requirements, and potential excise tax liability.
- We may be required to disclose personal information of investors to government or regulatory entities or face the possibility of a license being revoked or cancelled.
- We are subject to changes in laws, regulations and guidelines which could adversely affect our future business, financial condition and operations.
- Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business.
- Adverse legal, regulatory or political changes could have a material adverse effect on our current and planned operations.
- A drop in the wholesale or retail price of cannabis products in the geographic areas in which we operate would negatively impact our business, financial condition and results of operations.
- The future growth of the Company depends on the effectiveness and efficiency of its advertising and promotional expenditures to attract and retain customers.
- The Company depends on the popularity and acceptance of its brand portfolio.
- We may be subject to constraints on and differences in marketing our products under varying state laws.
- Future research may lead to findings that vaporizers, electronic cigarettes and related products are not safe for their intended use.
- Risks Related to our Business and Operations
- There is substantial doubt about our ability to continue as a going concern, and holders of our common shares could suffer a total loss of their investment. If we are unable to achieve our financial projections, we may need to raise additional capital to continue our operations. Such capital may not be available to us or may not be available at terms we deem acceptable, either of which could reduce our ability to compete and could negatively affect our business.
- Our business is dependent on skilled labor, equipment, parts, components and key inputs and any interruption or disruption could have a material adverse effect on our business, financial condition and results of operations.
- Our reliance on third-party suppliers and loss of these suppliers, manufacturers and contractors may have a material adverse effect on our business and operational results.
- Our actual financial position and results of operations may differ materially from the expectations of our management.
- We have incurred substantial indebtedness that may adversely affect our business, financial condition and results of operations and we may not be able to refinance, extend or repay this indebtedness on a timely basis or at all.
- The agreements governing our indebtedness contain various covenants that limit management’s discretion in the operation of our business and any default under our debt agreements could have a material adverse impact on our business and operations.
- We may not be able to generate sufficient cash flow to meet our debt service and repayment requirements and if our lenders exercise their rights in the event of a default it would have material adverse effect on our business, capital, financial condition and prospects and we would likely be forced to seek bankruptcy protection.
- Mark Scatterday has significant influence over the Company and may have interests that conflict with those of our other shareholders.
- Our shareholders may experience significant dilution as a result of the issuances of common shares upon exercise of our outstanding warrants or the trigger of the anti-dilution rights under the warrants, and the market price of our common shares could be adversely affected.
- We expect to incur significant ongoing costs and obligations related to our investment in infrastructure, growth, regulatory compliance and operations.
- There is no assurance that we will be able to develop our products, which could prevent us from ever becoming profitable.
- There is no assurance that our cash flows and debt or other financing will be sufficient to fund our operations.
- We are a holding company and are dependent on the earnings and distributions by our subsidiaries.
- We do not intend to pay dividends and any future dividends will depend upon, among other things, the results of our operations.
- We are exposed to the risk that our employees, independent contractors and consultants may engage in fraudulent or other illegal activity.
- We have been or may become subject to litigation, including for possible product liability claims, which may have a material adverse effect on our reputation, business, results from operations and financial condition.
- Failure to comply with applicable environmental laws, regulations and permit requirements may result in enforcement actions, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed and may include corrective measures requiring capital expenditures, installation of additional equipment or remedial actions.
- We may encounter unknown environmental risks.
- We are highly dependent on certain key personnel and if we are unable to attract and retain key personnel, we may not be able to compete effectively in the cannabis market.
- The market price of our securities has been and may continue to be volatile and subject to wide fluctuations.
- Since our securities are currently quoted on the OTCQB, our shareholders may face significant restrictions on the re-sale of our securities due to state “blue sky” laws.
- The Company has a history of losses and may continue to incur losses in the future.
- Our probable lack of business diversification could have a material adverse effect on our business.
- Our industry is experiencing rapid growth and consolidation that may cause us to lose key relationships and intensify competition.
- We may not be able to secure adequate or reliable sources of funding required to operate our business and meet consumer demand for our products.
- Product recalls could result in a material and adverse impact on our business, financial condition and results of operations.
- Our officers and directors may be engaged in a range of business activities which could result in a conflict of interest.
- Management may not be able to successfully implement and maintain adequate internal controls over financial reporting.
- We face costs of maintaining a public listing and being a reporting company in Canada and the U.S. which could adversely affect our business, financial condition and results of operations.
- Our emerging growth company status and our smaller reporting company status allows us certain exemptions from various reporting requirements.
- We may not be able to develop and maintain lasting relationships with consumers.
- Our web presence’s visibility is not limited by geography.
- We may have increased labor costs based on union activity.
- Risks Related to Macro-Economic Conditions
- Our operations and financial condition could be adversely impacted by a material downturn in global financial conditions.
- Increased prices and inflation could negatively impact our margin performance and our financial results.
- We may be adversely affected by boycotts, civil unrest, trade disputes, and other geo-political disruptions.
- Risks Related to our Intellectual Property and Information Technology
- We may be subject to risks related to the protection and enforcement of our intellectual property rights and may become subject to allegations that we are in violation of intellectual property rights of third parties.
- We may be forced to litigate to defend our intellectual property rights, or to defend against claims by third parties against us relating to intellectual property rights.
- We are reliant on information technology systems and may be subject to damaging cyber-attacks or security breaches.
Legal proceedings
Other than as described below, the Company is not aware of any material legal proceedings or regulatory actions that the Company is a party to, or that any of its property is the subject of, and no such proceedings are known by the Company to be contemplated.
The Company has been named as a defendant in several legal actions and is subject to various risks and contingencies arising in the normal course of business. Management is of the opinion that the outcome of these uncertainties will not have a material adverse effect on the Company’s financial position.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARBrad Hoch, Chief financial officer
- 14
- 15
- 16SEC EDGARMarshall Horowitz, Board member
- 17SEC EDGARAdam R. Draizin, Board member
- 18SEC EDGARGeorge Odden, Board member
- 19SEC EDGARArthur Smuck, Board member
- 20SEC EDGARD'Angela Simms, Board member
- 21SEC EDGARJane Batzofin, Board member
- 22SEC EDGARJohn R. Barravecchia, Board member
- 23SEC EDGARMark Scatterday, Board member
- 24SEC EDGARTimothy Alan Conder, Board member
- 25
- 26
- 27SEC EDGAROther events
- 28SEC EDGAROther events
- 29
- 30
- 31
- 32SEC EDGARResults of operations
- 33
- 34SEC EDGARShareholder vote; Other events
- 35SEC EDGARResults of operations
- 36SEC EDGARDebt or obligation accelerated
- 37SEC EDGARResults of operations
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46